Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClearPoint Neuro's earnings before interest and taxes (EBIT) for the
three
months ended in Jun. 2026 was $-9.96 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was $-29.33 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
ClearPoint Neuro's annualizedROC % for the quarter that ended in Jun. 2026 was -76.62%.
ClearPoint Neuro's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -155.90%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
ClearPoint Neuro's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -5.89%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro EBIT Related Terms
ClearPoint Neuro EBIT Historical Data
* Premium members only.
The historical data trend for ClearPoint Neuro's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ClearPoint Neuro's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClearPoint Neuro EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ClearPoint Neuro's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ClearPoint Neuro (CLPT) has a EBIT of $-29.33 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ClearPoint Neuro.
Is ClearPoint Neuro's EBIT too high?
ClearPoint Neuro's current EBIT is $-29.33 Mil. Overall, ClearPoint Neuro has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's EBIT compare to SI and PACB?
ClearPoint Neuro's EBIT of $-29.33 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on ClearPoint Neuro. ClearPoint Neuro's current EBIT is $-29.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.14, compared to a current price of $15.16 — trading 7.2% above its estimated fair value. The current EBIT is $-29.33 Mil. ClearPoint Neuro's overall GF Score™ is 63/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current EBIT is $-29.33 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClearPoint Neuro (CLPT) Overvalued in 2026?
Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be overvalued.
The current stock price of $15.16 is trading 7.2% above its estimated GF Value™ of $14.14.
GuruFocus considers ClearPoint Neuro to be Fairly Valued.
Key valuation signals for CLPT:
EBIT: $-29.33 Mil
GF Value™: $14.14 vs. price of $15.16 (7.2% above fair value)
No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
63GF Score
Get the complete analysis for CLPT
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPT has been successfully added to your 
